Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 191

1.

Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC).

Bamias A, Tzannis K, Harshman LC, Crabb SJ, Wong YN, Kumar Pal S, De Giorgi U, Ladoire S, Agarwal N, Yu EY, Niegisch G, Necchi A, Sternberg CN, Srinivas S, Alva A, Vaishampayan U, Cerbone L, Liontos M, Rosenberg J, Powles T, Bellmunt J, Galsky MD; RISC Investigators.

Ann Oncol. 2019 Nov 1;30(11):1841. doi: 10.1093/annonc/mdz214. No abstract available.

PMID:
31868903
2.

Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer.

Joshi K, Robert de Massy M, Ismail M, Reading JL, Uddin I, Woolston A, Hatipoglu E, Oakes T, Rosenthal R, Peacock T, Ronel T, Noursadeghi M, Turati V, Furness AJS, Georgiou A, Wong YNS, Ben Aissa A, Werner Sunderland M, Jamal-Hanjani M, Veeriah S, Birkbak NJ, Wilson GA, Hiley CT, Ghorani E, Guerra-Assunção JA, Herrero J, Enver T, Hadrup SR, Hackshaw A, Peggs KS, McGranahan N, Swanton C; TRACERx Consortium, Quezada SA, Chain B.

Nat Med. 2019 Oct;25(10):1549-1559. doi: 10.1038/s41591-019-0592-2. Epub 2019 Oct 7.

PMID:
31591606
3.

Reply to A. Vickers et al.

Jayadevappa R, Chhatre S, Gallo JJ, Wittink MN, Morales KH, Lee DI, Guzzo T, Vapiwala N, Wong YN, Newman DK, Van Arsdalen K, Malkowicz SB, Schwartz JS, Wein AJ.

J Clin Oncol. 2019 Dec 10;37(35):3463-3464. doi: 10.1200/JCO.19.01450. Epub 2019 Sep 30. No abstract available.

PMID:
31566992
4.

Results of a Real-world Study of Enzalutamide and Abiraterone Acetate With Prednisone Tolerability (REAAcT).

Shore ND, Saltzstein D, Sieber P, Mehlhaff B, Gervasi L, Phillips J, Wong YN, Pei H, McGowan T.

Clin Genitourin Cancer. 2019 Dec;17(6):457-463.e6. doi: 10.1016/j.clgc.2019.07.017. Epub 2019 Aug 6.

PMID:
31473120
5.

Multiple myeloma treatment patterns and clinical outcomes in the Latin America Haemato-Oncology (HOLA) Observational Study, 2008-2016.

de Moraes Hungria VT, Martínez-Baños DM, Peñafiel CR, Miguel CE, Vela-Ojeda J, Remaggi G, Duarte FB, Cao C, Cugliari MS, Santos T, Machnicki G, Fernandez M, Grings M, Ammann EM, Lin JH, Chen YW, Wong YN, Barreyro P.

Br J Haematol. 2020 Feb;188(3):383-393. doi: 10.1111/bjh.16124. Epub 2019 Aug 7.

6.

Comparative Survival Associated With Use of Targeted vs Nontargeted Therapy in Medicare Patients With Metastatic Renal Cell Carcinoma.

Li P, Jahnke J, Pettit AR, Wong YN, Doshi JA.

JAMA Netw Open. 2019 Jun 5;2(6):e195806. doi: 10.1001/jamanetworkopen.2019.5806. Erratum in: JAMA Netw Open. 2019 Jun 5;2(6):e197899.

7.

Neoantigen-directed immune escape in lung cancer evolution.

Rosenthal R, Cadieux EL, Salgado R, Bakir MA, Moore DA, Hiley CT, Lund T, Tanić M, Reading JL, Joshi K, Henry JY, Ghorani E, Wilson GA, Birkbak NJ, Jamal-Hanjani M, Veeriah S, Szallasi Z, Loi S, Hellmann MD, Feber A, Chain B, Herrero J, Quezada SA, Demeulemeester J, Van Loo P, Beck S, McGranahan N, Swanton C; TRACERx consortium.

Nature. 2019 Mar;567(7749):479-485. doi: 10.1038/s41586-019-1032-7. Epub 2019 Mar 20.

8.

Patient-Centered Preference Assessment to Improve Satisfaction With Care Among Patients With Localized Prostate Cancer: A Randomized Controlled Trial.

Jayadevappa R, Chhatre S, Gallo JJ, Wittink M, Morales KH, Lee DI, Guzzo TJ, Vapiwala N, Wong YN, Newman DK, Van Arsdalen K, Malkowicz SB, Schwartz JS, Wein AJ.

J Clin Oncol. 2019 Apr 20;37(12):964-973. doi: 10.1200/JCO.18.01091. Epub 2019 Mar 12.

PMID:
30860943
9.

Neoadjuvant Dose-dense Gemcitabine and Cisplatin in Muscle-invasive Bladder Cancer: Results of a Phase 2 Trial.

Anari F, O'Neill J, Choi W, Chen DYT, Haseebuddin M, Kutikov A, Dulaimi E, Alpaugh RK, Devarajan K, Greenberg RE, Bilusic M, Wong YN, Viterbo R, Hoffman-Censits JH, Lallas CD, Trabulsi EJ, Smaldone M, Geynisman DM, Zibelman M, Lin J, Kelly WK, Uzzo R, McConkey D, Plimack ER.

Eur Urol Oncol. 2018 May;1(1):54-60. doi: 10.1016/j.euo.2018.02.007. Epub 2018 Jun 6.

10.

Urine-derived lymphocytes as a non-invasive measure of the bladder tumor immune microenvironment.

Wong YNS, Joshi K, Khetrapal P, Ismail M, Reading JL, Sunderland MW, Georgiou A, Furness AJS, Ben Aissa A, Ghorani E, Oakes T, Uddin I, Tan WS, Feber A, McGovern U, Swanton C, Freeman A, Marafioti T, Briggs TP, Kelly JD, Powles T, Peggs KS, Chain BM, Linch MD, Quezada SA.

J Exp Med. 2018 Nov 5;215(11):2748-2759. doi: 10.1084/jem.20181003. Epub 2018 Sep 26.

11.

Temporal trends and characteristics of clinical trials for which only one racial or ethnic group is eligible.

Egleston BL, Pedraza O, Wong YN, Griffin CL, Ross EA, Beck JR.

Contemp Clin Trials Commun. 2018 Jan 31;9:135-142. doi: 10.1016/j.conctc.2018.01.004. eCollection 2018 Mar.

12.

Provider and patient burdens of obtaining oral anticancer medications.

Geynisman DM, Meeker CR, Doyle JL, Handorf EA, Bilusic M, Plimack ER, Wong YN.

Am J Manag Care. 2018 Apr 1;24(4):e128-e133.

13.

Treating Second Breast Events After Breast-Conserving Surgery for Ductal Carcinoma in Situ.

Hassett MJ, Jiang W, Hughes ME, Edge S, Javid SH, Niland JC, Theriault R, Wong YN, Schrag D, Punglia RS.

J Natl Compr Canc Netw. 2018 Apr;16(4):387-394. doi: 10.6004/jnccn.2018.7003.

PMID:
29632058
14.

Patient-centered recruitment and retention for a randomized controlled study.

Chhatre S, Jefferson A, Cook R, Meeker CR, Kim JH, Hartz KM, Wong YN, Caruso A, Newman DK, Morales KH, Jayadevappa R.

Trials. 2018 Mar 27;19(1):205. doi: 10.1186/s13063-018-2578-7.

15.

Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies.

Arce Vargas F, Furness AJS, Litchfield K, Joshi K, Rosenthal R, Ghorani E, Solomon I, Lesko MH, Ruef N, Roddie C, Henry JY, Spain L, Ben Aissa A, Georgiou A, Wong YNS, Smith M, Strauss D, Hayes A, Nicol D, O'Brien T, Mårtensson L, Ljungars A, Teige I, Frendéus B; TRACERx Melanoma; TRACERx Renal; TRACERx Lung consortia, Pule M, Marafioti T, Gore M, Larkin J, Turajlic S, Swanton C, Peggs KS, Quezada SA.

Cancer Cell. 2018 Apr 9;33(4):649-663.e4. doi: 10.1016/j.ccell.2018.02.010. Epub 2018 Mar 22.

16.

Association of high cost sharing and targeted therapy initiation among elderly Medicare patients with metastatic renal cell carcinoma.

Li P, Wong YN, Jahnke J, Pettit AR, Doshi JA.

Cancer Med. 2018 Jan;7(1):75-86. doi: 10.1002/cam4.1262. Epub 2017 Dec 1.

17.

National Study of Burnout and Career Satisfaction Among Physician Assistants in Oncology: Implications for Team-Based Care.

Tetzlaff ED, Hylton HM, DeMora L, Ruth K, Wong YN.

J Oncol Pract. 2018 Jan;14(1):e11-e22. doi: 10.1200/JOP.2017.025544. Epub 2017 Nov 30.

18.

Radium-223 Safety, Efficacy, and Concurrent Use with Abiraterone or Enzalutamide: First U.S. Experience from an Expanded Access Program.

Sartor O, Vogelzang NJ, Sweeney C, Fernandez DC, Almeida F, Iagaru A, Brown A Jr, Smith MR, Agrawal M, Dicker AP, Garcia JA, Lutzky J, Wong YN, Petrenciuc O, Gratt J, Shore ND, Morris MJ; U.S. Expanded Access Program Investigators.

Oncologist. 2018 Feb;23(2):193-202. doi: 10.1634/theoncologist.2017-0413. Epub 2017 Nov 28.

19.

Phase 2 Study of Weekly Paclitaxel Plus Estramustine in Metastatic Hormone-Refractory Prostate Carcinoma: ECOG-ACRIN Cancer Research Group (E1898) Trial.

Wong YN, Manola J, Hudes GR, Roth BJ, Moul JW, Barsevick AM, Scher RM, Volk MJ, Vaughn DJ, Williams SD, Fisch MJ, Cella D, Carducci MA, Wilding G.

Clin Genitourin Cancer. 2018 Apr;16(2):e315-e322. doi: 10.1016/j.clgc.2017.10.001. Epub 2017 Oct 16.

20.

Validation of Molecular Pathology Codes for the Identification of Mutational Testing in Lung and Colon Cancer.

Vachani A, Wong YN, Israelite J, Mitra N, Hin S, Yang L, Smith-McLallen A, Armstrong K, Groeneveld PW, Epstein AJ.

Med Care. 2017 Dec;55(12):e131-e136. doi: 10.1097/MLR.0000000000000484.

PMID:
29135776
21.

Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution.

McGranahan N, Rosenthal R, Hiley CT, Rowan AJ, Watkins TBK, Wilson GA, Birkbak NJ, Veeriah S, Van Loo P, Herrero J, Swanton C; TRACERx Consortium.

Cell. 2017 Nov 30;171(6):1259-1271.e11. doi: 10.1016/j.cell.2017.10.001. Epub 2017 Oct 26.

22.

Clinical risk score to predict likelihood of recurrence after ductal carcinoma in situ treated with breast-conserving surgery.

Punglia RS, Jiang W, Lipsitz SR, Hughes ME, Schnitt SJ, Hassett MJ, Nekhlyudov L, Achacoso N, Edge S, Javid SH, Niland JC, Theriault RL, Wong YN, Habel LA.

Breast Cancer Res Treat. 2018 Feb;167(3):751-759. doi: 10.1007/s10549-017-4553-5. Epub 2017 Oct 28.

PMID:
29079937
23.

Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC).

Bamias A, Tzannis K, Harshman LC, Crabb SJ, Wong YN, Kumar Pal S, De Giorgi U, Ladoire S, Agarwal N, Yu EY, Niegisch G, Necchi A, Sternberg CN, Srinivas S, Alva A, Vaishampayan U, Cerbone L, Liontos M, Rosenberg J, Powles T, Bellmunt J, Galsky MD; RISC Investigators.

Ann Oncol. 2018 Feb 1;29(2):361-369. doi: 10.1093/annonc/mdx692. Erratum in: Ann Oncol. 2019 Nov;30(11):1841.

24.

Distress and Financial Distress in Adults With Cancer: An Age-Based Analysis.

Meeker CR, Wong YN, Egleston BL, Hall MJ, Plimack ER, Martin LP, von Mehren M, Lewis BR, Geynisman DM.

J Natl Compr Canc Netw. 2017 Oct;15(10):1224-1233. doi: 10.6004/jnccn.2017.0161.

PMID:
28982748
25.

Latent Class Survival Models Linked by Principal Stratification to Investigate Heterogenous Survival Subgroups Among Individuals With Early-Stage Kidney Cancer.

Egleston BL, Uzzo RG, Wong YN.

J Am Stat Assoc. 2017;112(518):534-546. doi: 10.1080/01621459.2016.1240078. Epub 2016 Oct 7.

26.

Intratumoural evolutionary landscape of high-risk prostate cancer: the PROGENY study of genomic and immune parameters.

Linch M, Goh G, Hiley C, Shanmugabavan Y, McGranahan N, Rowan A, Wong YNS, King H, Furness A, Freeman A, Linares J, Akarca A, Herrero J, Rosenthal R, Harder N, Schmidt G, Wilson GA, Birkbak NJ, Mitter R, Dentro S, Cathcart P, Arya M, Johnston E, Scott R, Hung M, Emberton M, Attard G, Szallasi Z, Punwani S, Quezada SA, Marafioti T, Gerlinger M, Ahmed HU, Swanton C.

Ann Oncol. 2017 Oct 1;28(10):2472-2480. doi: 10.1093/annonc/mdx355.

27.

Lack of Effectiveness of Postchemotherapy Lymphadenectomy in Bladder Cancer Patients with Clinical Evidence of Metastatic Pelvic or Retroperitoneal Lymph Nodes Only: A Propensity Score-based Analysis.

Necchi A, Mariani L, Lo Vullo S, Yu EY, Woods ME, Wong YN, Harshman LC, Alva A, Sternberg CN, Bamias A, Grivas P, Koshkin VS, Roghmann F, Dobruch J, Eigl BJ, Nappi L, Milowsky MI, Niegisch G, Pal SK, De Giorgi U, Recine F, Vaishampayan U, Berthold DD, Bowles DW, Baniel J, Theodore C, Ladoire S, Srinivas S, Agarwal N, Crabb S, Sridhar S, Golshayan AR, Ohlmann C, Xylinas E, Powles T, Rosenberg JE, Bellmunt J, van Rhijn B, Galsky MD, Hendricksen K; Young Academic Urologists-Urothelial Carcinoma Group-European Association of Urology and the Retrospective International Study of Invasive/Advanced Cancer of the Urothelium group.

Eur Urol Focus. 2019 Mar;5(2):242-249. doi: 10.1016/j.euf.2017.05.006. Epub 2017 Jun 3.

PMID:
28753897
28.

Robot-assisted Versus Open Radical Cystectomy in Patients Receiving Perioperative Chemotherapy for Muscle-invasive Bladder Cancer: The Oncologist's Perspective from a Multicentre Study.

Necchi A, Pond GR, Smaldone MC, Pal SK, Chan K, Wong YN, Viterbo R, Sonpavde G, Harshman LC, Crabb S, Alva A, Chowdhury S, De Giorgi U, Srinivas S, Agarwal N, Bamias A, Baniel J, Golshayan AR, Ladoire S, Sternberg CN, Cerbone L, Yu EY, Bellmunt J, Vaishampayan U, Niegisch G, Hussain S, Bowles DW, Morales-Barrera R, Milowsky MI, Theodore C, Berthold DR, Sridhar SS, Powles T, Rosenberg JE, Galsky MD; Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC).

Eur Urol Focus. 2018 Dec;4(6):937-945. doi: 10.1016/j.euf.2017.03.011. Epub 2017 Mar 31.

29.

Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis.

Turajlic S, Litchfield K, Xu H, Rosenthal R, McGranahan N, Reading JL, Wong YNS, Rowan A, Kanu N, Al Bakir M, Chambers T, Salgado R, Savas P, Loi S, Birkbak NJ, Sansregret L, Gore M, Larkin J, Quezada SA, Swanton C.

Lancet Oncol. 2017 Aug;18(8):1009-1021. doi: 10.1016/S1470-2045(17)30516-8. Epub 2017 Jul 7.

30.

Evolving adoptive cellular therapies in urological malignancies.

Wong YNS, Joshi K, Pule M, Peggs KS, Swanton C, Quezada SA, Linch M.

Lancet Oncol. 2017 Jun;18(6):e341-e353. doi: 10.1016/S1470-2045(17)30327-3. Review.

PMID:
28593860
31.

Comparative effectiveness of prostate cancer treatments for patient-centered outcomes: A systematic review and meta-analysis (PRISMA Compliant).

Jayadevappa R, Chhatre S, Wong YN, Wittink MN, Cook R, Morales KH, Vapiwala N, Newman DK, Guzzo T, Wein AJ, Malkowicz SB, Lee DI, Schwartz JS, Gallo JJ.

Medicine (Baltimore). 2017 May;96(18):e6790. doi: 10.1097/MD.0000000000006790. Review.

32.

Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution.

Abbosh C, Birkbak NJ, Wilson GA, Jamal-Hanjani M, Constantin T, Salari R, Le Quesne J, Moore DA, Veeriah S, Rosenthal R, Marafioti T, Kirkizlar E, Watkins TBK, McGranahan N, Ward S, Martinson L, Riley J, Fraioli F, Al Bakir M, Grönroos E, Zambrana F, Endozo R, Bi WL, Fennessy FM, Sponer N, Johnson D, Laycock J, Shafi S, Czyzewska-Khan J, Rowan A, Chambers T, Matthews N, Turajlic S, Hiley C, Lee SM, Forster MD, Ahmad T, Falzon M, Borg E, Lawrence D, Hayward M, Kolvekar S, Panagiotopoulos N, Janes SM, Thakrar R, Ahmed A, Blackhall F, Summers Y, Hafez D, Naik A, Ganguly A, Kareht S, Shah R, Joseph L, Marie Quinn A, Crosbie PA, Naidu B, Middleton G, Langman G, Trotter S, Nicolson M, Remmen H, Kerr K, Chetty M, Gomersall L, Fennell DA, Nakas A, Rathinam S, Anand G, Khan S, Russell P, Ezhil V, Ismail B, Irvin-Sellers M, Prakash V, Lester JF, Kornaszewska M, Attanoos R, Adams H, Davies H, Oukrif D, Akarca AU, Hartley JA, Lowe HL, Lock S, Iles N, Bell H, Ngai Y, Elgar G, Szallasi Z, Schwarz RF, Herrero J, Stewart A, Quezada SA, Peggs KS, Van Loo P, Dive C, Lin CJ, Rabinowitz M, Aerts HJWL, Hackshaw A, Shaw JA, Zimmermann BG; TRACERx consortium; PEACE consortium, Swanton C.

Nature. 2017 Apr 26;545(7655):446-451. doi: 10.1038/nature22364. Erratum in: Nature. 2017 Dec 20;:.

33.

Tracking the Evolution of Non-Small-Cell Lung Cancer.

Jamal-Hanjani M, Wilson GA, McGranahan N, Birkbak NJ, Watkins TBK, Veeriah S, Shafi S, Johnson DH, Mitter R, Rosenthal R, Salm M, Horswell S, Escudero M, Matthews N, Rowan A, Chambers T, Moore DA, Turajlic S, Xu H, Lee SM, Forster MD, Ahmad T, Hiley CT, Abbosh C, Falzon M, Borg E, Marafioti T, Lawrence D, Hayward M, Kolvekar S, Panagiotopoulos N, Janes SM, Thakrar R, Ahmed A, Blackhall F, Summers Y, Shah R, Joseph L, Quinn AM, Crosbie PA, Naidu B, Middleton G, Langman G, Trotter S, Nicolson M, Remmen H, Kerr K, Chetty M, Gomersall L, Fennell DA, Nakas A, Rathinam S, Anand G, Khan S, Russell P, Ezhil V, Ismail B, Irvin-Sellers M, Prakash V, Lester JF, Kornaszewska M, Attanoos R, Adams H, Davies H, Dentro S, Taniere P, O'Sullivan B, Lowe HL, Hartley JA, Iles N, Bell H, Ngai Y, Shaw JA, Herrero J, Szallasi Z, Schwarz RF, Stewart A, Quezada SA, Le Quesne J, Van Loo P, Dive C, Hackshaw A, Swanton C; TRACERx Consortium.

N Engl J Med. 2017 Jun 1;376(22):2109-2121. doi: 10.1056/NEJMoa1616288. Epub 2017 Apr 26.

34.

Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors.

Arce Vargas F, Furness AJS, Solomon I, Joshi K, Mekkaoui L, Lesko MH, Miranda Rota E, Dahan R, Georgiou A, Sledzinska A, Ben Aissa A, Franz D, Werner Sunderland M, Wong YNS, Henry JY, O'Brien T, Nicol D, Challacombe B, Beers SA; Melanoma TRACERx Consortium; Renal TRACERx Consortium; Lung TRACERx Consortium, Turajlic S, Gore M, Larkin J, Swanton C, Chester KA, Pule M, Ravetch JV, Marafioti T, Peggs KS, Quezada SA.

Immunity. 2017 Apr 18;46(4):577-586. doi: 10.1016/j.immuni.2017.03.013. Epub 2017 Apr 11.

35.

A hospital-wide screening programme to control an outbreak of vancomycin-resistant enterococci in a large tertiary hospital in Hong Kong.

Lai CK, Wong SY, Lee SS, Siu HK, Chiu CY, Tsang DN, Ip MP, Hung CT.

Hong Kong Med J. 2017 Apr;23(2):140-9. doi: 10.12809/hkmj164939. Epub 2017 Feb 24.

36.

Patterns of Bladder Preservation Therapy Utilization for Muscle-Invasive Bladder Cancer.

Rose TL, Deal AM, Ladoire S, Créhange G, Galsky MD, Rosenberg JE, Bellmunt J, Wimalasingham A, Wong YN, Harshman LC, Chowdhury S, Niegisch G, Liontos M, Yu EY, Pal SK, Chen RC, Wang AZ, Nielsen ME, Smith AB, Milowsky MI; Retrospective International Study of Cancers of the Urothelial Tract (RISC) Investigators.

Bladder Cancer. 2016 Oct 27;2(4):405-413. doi: 10.3233/BLC-160072.

37.

Venous thromboembolism in metastatic urothelial carcinoma or variant histologies: incidence, associative factors, and effect on survival.

Ramos JD, Casey MF, Crabb SJ, Bamias A, Harshman LC, Wong YN, Bellmunt J, De Giorgi U, Ladoire S, Powles T, Pal SK, Niegisch G, Recine F, Alva A, Agarwal N, Necchi A, Vaishampayan UN, Rosenberg JE, Galsky MD, Yu EY; RISC Investigators.

Cancer Med. 2017 Jan;6(1):186-194. doi: 10.1002/cam4.986. Epub 2016 Dec 20.

38.

Small-Cell Carcinoma of the Bladder: 20-Year Single-Institution Retrospective Review.

Jung K, Ghatalia P, Litwin S, Horwitz EM, Uzzo RG, Greenberg RE, Viterbo R, Geynisman DM, Kutikov A, Plimack ER, Smaldone MC, Wong YN, Bilusic M.

Clin Genitourin Cancer. 2017 Jun;15(3):e337-e343. doi: 10.1016/j.clgc.2016.09.005. Epub 2016 Sep 30. Review.

PMID:
27991416
39.

Understanding Treatment Disconnect and Mortality Trends in Renal Cell Carcinoma Using Tumor Registry Data.

Smaldone MC, Egleston B, Hollingsworth JM, Hollenbeck BK, Miller DC, Morgan TM, Kim SP, Malhotra A, Handorf E, Wong YN, Uzzo RG, Kutikov A.

Med Care. 2017 Apr;55(4):398-404. doi: 10.1097/MLR.0000000000000657.

40.

Addressing Patients' Priorities as a Strategy to Improve Value.

Wong YN, Roach N, Meropol NJ.

Oncologist. 2016 Nov;21(11):1279-1282. doi: 10.1634/theoncologist.2016-0184. Epub 2016 Oct 14. No abstract available.

41.

Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC).

Necchi A, Sonpavde G, Lo Vullo S, Giardiello D, Bamias A, Crabb SJ, Harshman LC, Bellmunt J, De Giorgi U, Sternberg CN, Cerbone L, Ladoire S, Wong YN, Yu EY, Chowdhury S, Niegisch G, Srinivas S, Vaishampayan UN, Pal SK, Agarwal N, Alva A, Baniel J, Golshayan AR, Morales-Barrera R, Bowles DW, Milowsky MI, Theodore C, Berthold DR, Daugaard G, Sridhar SS, Powles T, Rosenberg JE, Galsky MD, Mariani L; RISC Investigators.

Eur Urol. 2017 Feb;71(2):281-289. doi: 10.1016/j.eururo.2016.09.042. Epub 2016 Oct 8.

42.

The Khorana Score in Predicting Venous Thromboembolism for Patients With Metastatic Urothelial Carcinoma and Variant Histology Treated With Chemotherapy.

Ramos JD, Casey MF, Bamias A, De Giorgi U, Bellmunt J, Harshman LC, Ladoire S, Wong YN, Alva AS, Rosenberg JE, Galsky MD, Yu EY; Retrospective International Study of Cancers of the Urothelium (RISC) Investigators.

Clin Appl Thromb Hemost. 2017 Oct;23(7):755-760. doi: 10.1177/1076029616668405. Epub 2016 Sep 16.

43.

Biology is Destiny: A Case of Adrenocortical Carcinoma Diagnosed and Resected at Inception in a Patient Under Close Surveillance for Lung Cancer.

Miron B, Ristau BT, Tomaszewski JJ, Jones J, Milestone B, Wong YN, Uzzo RG, Edmondson D, Scott W, Kutikov A.

Urol Case Rep. 2016 Aug 27;9:9-11. doi: 10.1016/j.eucr.2016.07.009. eCollection 2016 Nov.

44.

Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial.

Rini BI, Dorff TB, Elson P, Rodriguez CS, Shepard D, Wood L, Humbert J, Pyle L, Wong YN, Finke JH, Rayman PA, Larkin JM, Garcia JA, Plimack ER.

Lancet Oncol. 2016 Sep;17(9):1317-24. doi: 10.1016/S1470-2045(16)30196-6. Epub 2016 Aug 3.

PMID:
27498080
45.

Subtype-Dependent Relationship Between Young Age at Diagnosis and Breast Cancer Survival.

Partridge AH, Hughes ME, Warner ET, Ottesen RA, Wong YN, Edge SB, Theriault RL, Blayney DW, Niland JC, Winer EP, Weeks JC, Tamimi RM.

J Clin Oncol. 2016 Sep 20;34(27):3308-14. doi: 10.1200/JCO.2015.65.8013. Epub 2016 Aug 1.

PMID:
27480155
46.

Chemotherapy use and adoption of new agents is affected by age and comorbidities in patients with metastatic colorectal cancer.

Vijayvergia N, Li T, Wong YN, Hall MJ, Cohen SJ, Dotan E.

Cancer. 2016 Oct 15;122(20):3191-3198. doi: 10.1002/cncr.30077. Epub 2016 Jul 5.

47.

Relationships Among Financial Distress, Emotional Distress, and Overall Distress in Insured Patients With Cancer.

Meeker CR, Geynisman DM, Egleston BL, Hall MJ, Mechanic KY, Bilusic M, Plimack ER, Martin LP, von Mehren M, Lewis B, Wong YN.

J Oncol Pract. 2016 Jul;12(7):e755-64. doi: 10.1200/JOP.2016.011049. Epub 2016 Jun 21.

48.

Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial.

Haas NB, Manola J, Uzzo RG, Flaherty KT, Wood CG, Kane C, Jewett M, Dutcher JP, Atkins MB, Pins M, Wilding G, Cella D, Wagner L, Matin S, Kuzel TM, Sexton WJ, Wong YN, Choueiri TK, Pili R, Puzanov I, Kohli M, Stadler W, Carducci M, Coomes R, DiPaola RS.

Lancet. 2016 May 14;387(10032):2008-16. doi: 10.1016/S0140-6736(16)00559-6. Epub 2016 Mar 9. Erratum in: Lancet. 2016 May 14;387(10032):1998.

49.

The Parity Paradigm: Can Legislation Help Reduce the Cost Burden of Oral Anticancer Medications?

Kircher SM, Meeker CR, Nimeiri H, Geynisman DM, Zafar SY, Shankaran V, de Souza J, Wong YN.

Value Health. 2016 Jan;19(1):88-98. doi: 10.1016/j.jval.2015.10.005. Epub 2015 Nov 26.

50.

Drug Supply Chain Security Act and Oral Anticancer Medications: Are We Shortchanging Our Patients?

Geynisman DM, Wong YN.

JAMA Oncol. 2016 Mar;2(3):295-6. doi: 10.1001/jamaoncol.2015.5345. No abstract available.

PMID:
26720609

Supplemental Content

Loading ...
Support Center